Azitra Inc (AZTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Azitra Inc (AZTR) has a cash flow conversion efficiency ratio of -0.761x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($3.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Azitra Inc to measure how much of total assets are equity-financed.
Azitra Inc - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Azitra Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Azitra Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Azitra Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Azitra Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Halo Technologies Holdings Ltd
AU:HAL
|
0.345x |
|
WestKam Gold Corp
V:WKG
|
0.023x |
|
Murchison Minerals Ltd
V:MUR
|
-0.773x |
|
Klondike Silver Corp
V:KS
|
0.001x |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
N/A |
|
Movinn AS
CO:MOVINN
|
-0.344x |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
-0.005x |
|
Labat Africa Ltd
JSE:LAB
|
0.005x |
Annual Cash Flow Conversion Efficiency for Azitra Inc (2021–2025)
The table below shows the annual cash flow conversion efficiency of Azitra Inc from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Azitra Inc (AZTR) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.80 Billion | $-11.22 Million | -0.003x | +99.83% |
| 2024-12-31 | $5.70 Million | $-10.18 Million | -1.787x | +29.29% |
| 2023-12-31 | $2.91 Million | $-7.36 Million | -2.527x | -1197.56% |
| 2022-12-31 | $-36.26 Million | $-8.35 Million | 0.230x | -26.46% |
| 2021-12-31 | $-25.77 Million | $-8.07 Million | 0.313x | -- |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more